Real-world view of systemic therapies for advanced HCC at a single center

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a retrospective cohort study conducted at the Tropical Medicine Department of Mansoura University Hospitals. It will include adults with advanced HCC who receive systemic therapy between June 2022 and November 2024 and meet liver function and performance status criteria (Child-Pugh A, ECOG 0-1). Data will be collected from medical records, imaging, and lab tests, with follow-up every three months to monitor disease progression and treatment outcomes. Analysis will summarize baseline characteristics and outcomes using SPSS software. The study aims to describe real-world treatment patterns and associated outcomes in this specific patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patient with HCC
* Child-Pugh class A, B7
* Performance state 0-1 (Eastern Cooperative Oncology Group (ECOG scale).
* Barcelona Clinic Liver Cancer (BCLC) stage C or BCLC stage B with diffuse, infiltrative or extensive bilobar involvement or BCLC stage B with tumor progression after TACE.

Exclusion Criteria:

* patient with other tumor than HCC
* Child-Turcotte-Pugh score B (8,9) and C.
* Patients eligible for treatment other than systemic therapy according to Barcelona Clinic liver cancer.

Where it's running

• Mansoura University Hospitals
  Al Mansurah, Dakahlia Governorate, Egypt Recruiting

Study contacts

• Study coordinator: Mahmoud M El-Bendary, PhD
• Email: mmelbendary@gmail.com
• Phone: +201002592205

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• TACE plus SBRT before liver transplant for hepatocellular carcinoma

  This study tests whether adding SBRT to standard TACE helps liver transplant patients with hepatocellular carcinoma see better outcomes.

  Recruiting AIO-Studien-gGmbH · München · NCT07924943

• Personalized 3D-printed liver models to pick adjuvant therapy after liver cancer surgery

  Doctors test whether a patient’s own 3D-bioprinted liver model can help choose the best additional treatment to lower the chance of cancer coming back after liver surgery.

  Recruiting The University of Hong Kong · Hong Kong · NCT07839767

• Laparoscopic liver and spleen removal for small liver cancer in people with cirrhosis and enlarged spleen

  This study tests whether removing part of the liver and the spleen during one operation helps people with small liver cancers and hypersplenism by improving liver function and immune balance.

  Recruiting Northern Jiangsu People's Hospital · Yangzhou, Jiangsu · NCT07811687

• ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients

  This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.

  Recruiting at 2 sites Tam Anh Research Institute · Hanoi, Hanoi and 1 other locations · NCT07808164

• Iparomlimab and Tuvonralimab with SBRT and Lenvatinib for Potentially Resectable Intermediate-Stage HCC

  This trial tests whether adding two antibodies together with SBRT and lenvatinib can improve outcomes for adults with potentially resectable intermediate-stage hepatocellular carcinoma.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07801287

• Iparomlimab and Tuvonralimab with Lenvatinib, Radiotherapy, and HAIC in HCC with PVTT

  This trial tests a multi-drug approach to see if it can control liver cancer that has grown into the portal vein in adults.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07776080

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.